Business Context and Reporting Period
Company: Medline Inc. (MDLN)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: Medline is the largest provider of medical-surgical (med-surg) products and supply chain solutions. The company operates through two reportable segments: Medline Brand (manufacturing and selling proprietary products) and Supply Chain Solutions (distributing third-party products and logistics services).
Key Event: The company completed its Initial Public Offering (IPO) on December 18, 2025, transitioning from a private partnership (Medline Holdings, LP) to a public holding company structure. The IPO generated net proceeds of approximately $7.0 billion.
Key Financial Metrics
| Metric (in millions) | 2025 | 2024 |
|---|---|---|
| Net Sales | $28,432 | $25,507 |
| Gross Profit | $7,518 | $6,976 |
| Gross Margin | 26.4% | 27.3% |
| Operating Income | $2,212 | $2,146 |
| Net Income | $1,157 | $1,200 |
| Net Income Margin | 4.1% | 4.7% |
| Adjusted EBITDA | $3,467 | $3,361 |
| Adjusted EBITDA Margin | 12.2% | 13.2% |
| Cash from Operating Activities | $1,744 | $1,769 |
| Total Debt (Gross) | $12,755 | $16,757 |
| Cash and Cash Equivalents | $1,939 | $199 |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 11.5% to $28.4 billion, driven primarily by organic volume growth (10.5%) and acquisitions (0.9%). Prime Vendor net sales grew 12.5% to $18.0 billion.
- Margin Compression: Gross margin decreased 90 basis points to 26.4%, primarily due to a 115 basis point negative impact from higher import costs associated with tariffs. Adjusted EBITDA margin declined 100 basis points to 12.2%.
- Net Income Decline: Net income decreased 3.6% to $1.2 billion, despite stable pre-tax income, due to a higher provision for income taxes (increased 97.8%) driven by global minimum tax (Pillar Two) rules.
- Debt Reduction: Total debt decreased by approximately $4.0 billion. The company used IPO proceeds to repay all outstanding Euro Term Loans ($731 million) and a significant portion of Dollar Term Loans ($3.29 billion).
- Segment Performance:
- Medline Brand: Sales up 9.6% to $13.7 billion; Adjusted EBITDA up 2.0% to $3.3 billion.
- Supply Chain Solutions: Sales up 13.2% to $14.7 billion; Adjusted EBITDA up 24.4% to $0.8 billion.
Guidance, Outlook, and Risks
- Tariff Impact: Management estimates an incremental net adverse impact to income before taxes of approximately $200 million for fiscal year 2026 due to tariffs, compared to $290 million in 2025.
- Capital Expenditures: Net capital expenditures are expected to be approximately $500 million in 2026, focused on expanding manufacturing and distribution facilities and automation.
- Tax Receivable Agreement (TRA): The company has recorded a TRA liability of $3.5 billion. This agreement requires Medline Inc. to pay 90% of certain tax benefits realized from the IPO to pre-IPO owners. Management notes that payments under this agreement could be substantial and may exceed actual cash tax benefits realized.
- Key Risks:
- Regulatory: Extensive oversight by the FDA and other agencies regarding medical devices, data privacy (HIPAA, GDPR), and healthcare fraud/abuse laws.
- Supply Chain: Dependence on third-party manufacturers and exposure to global shipping costs and geopolitical conflicts.
- Customer Concentration: Top five U.S. customers represented 11.3% of net sales; 69% of consolidated net sales came from hospitals under contract with the three largest Group Purchasing Organizations (GPOs).
- Legal: Ongoing litigation regarding ethylene oxide (EtO) emissions and product liability claims.
Investor Verification Checklist
- Tariff Mitigation: Verify the company's ability to pass on tariff-related cost increases to customers without losing market share, given the competitive pressure in the med-surg industry.
- Tax Receivable Agreement Liability: Assess the cash flow impact of the $3.5 billion TRA liability and the potential for future payments to exceed actual tax savings.
- Prime Vendor Retention: Monitor the 98% average Prime Vendor retention rate and the success of converting Supply Chain Solutions products to higher-margin Medline Brand products.
- Debt Covenants: Review compliance with the springing financial covenant (first lien net leverage ratio) in the Credit Agreement, which is triggered if revolver borrowings exceed 35% of commitments.
- Legal Reserves: Confirm the status of EtO litigation settlements and any potential exposure from the California hazardous waste investigation mentioned in the filing.